Stockreport

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF TAR-200 provides durable CRs in patients with Bacillus Calmette-Guérin (BCG) – unresponsive high-risk non – muscle-invasive bladder cancer (NMIBC) with carcinoma in sit [Read more]